We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Astrazeneca (AZN) Registers a Bigger Fall Than the Market: Important Facts to Note
Read MoreHide Full Article
In the latest trading session, Astrazeneca (AZN - Free Report) closed at $164.21, marking a -1.17% move from the previous day. The stock trailed the S&P 500, which registered a daily loss of 0.17%. Meanwhile, the Dow lost 0.26%, and the Nasdaq, a tech-heavy index, lost 0.09%.
Heading into today, shares of the pharmaceutical had gained 2.48% over the past month, outpacing the Medical sector's loss of 0.67% and the S&P 500's loss of 0.24%.
The investment community will be closely monitoring the performance of Astrazeneca in its forthcoming earnings report. The company is scheduled to release its earnings on October 30, 2026. The company is predicted to post an EPS of $2.17, indicating a 8.82% decline compared to the equivalent quarter last year. Alongside, our most recent consensus estimate is anticipating revenue of $16.07 billion, indicating a 5.82% upward movement from the same quarter last year.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $9.37 per share and revenue of $63.12 billion, indicating changes of +2.29% and +7.45%, respectively, compared to the previous year.
It is also important to note the recent changes to analyst estimates for Astrazeneca. Recent revisions tend to reflect the latest near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 8.05% decrease. Astrazeneca presently features a Zacks Rank of #3 (Hold).
With respect to valuation, Astrazeneca is currently being traded at a Forward P/E ratio of 17.73. For comparison, its industry has an average Forward P/E of 25.2, which means Astrazeneca is trading at a discount to the group.
One should further note that AZN currently holds a PEG ratio of 1.4. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. As of the close of trade yesterday, the Medical - Biomedical and Genetics industry held an average PEG ratio of 1.95.
The Medical - Biomedical and Genetics industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 184, placing it within the bottom 26% of over 250 industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Astrazeneca (AZN) Registers a Bigger Fall Than the Market: Important Facts to Note
In the latest trading session, Astrazeneca (AZN - Free Report) closed at $164.21, marking a -1.17% move from the previous day. The stock trailed the S&P 500, which registered a daily loss of 0.17%. Meanwhile, the Dow lost 0.26%, and the Nasdaq, a tech-heavy index, lost 0.09%.
Heading into today, shares of the pharmaceutical had gained 2.48% over the past month, outpacing the Medical sector's loss of 0.67% and the S&P 500's loss of 0.24%.
The investment community will be closely monitoring the performance of Astrazeneca in its forthcoming earnings report. The company is scheduled to release its earnings on October 30, 2026. The company is predicted to post an EPS of $2.17, indicating a 8.82% decline compared to the equivalent quarter last year. Alongside, our most recent consensus estimate is anticipating revenue of $16.07 billion, indicating a 5.82% upward movement from the same quarter last year.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $9.37 per share and revenue of $63.12 billion, indicating changes of +2.29% and +7.45%, respectively, compared to the previous year.
It is also important to note the recent changes to analyst estimates for Astrazeneca. Recent revisions tend to reflect the latest near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 8.05% decrease. Astrazeneca presently features a Zacks Rank of #3 (Hold).
With respect to valuation, Astrazeneca is currently being traded at a Forward P/E ratio of 17.73. For comparison, its industry has an average Forward P/E of 25.2, which means Astrazeneca is trading at a discount to the group.
One should further note that AZN currently holds a PEG ratio of 1.4. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. As of the close of trade yesterday, the Medical - Biomedical and Genetics industry held an average PEG ratio of 1.95.
The Medical - Biomedical and Genetics industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 184, placing it within the bottom 26% of over 250 industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.